Cetera Advisor Networks LLC Neurocrine Biosciences Inc Transaction History

Cetera Advisor Networks LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$130.4 - $143.74 $122,706 - $135,259	-941 Reduced 16.37%	4,806 $662,000
Q4 2023 Feb 13, 2024	BUY	$106.07 - $132.76 $954 - $1,194	9 Added 0.16%	5,747 $757,000
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $139,243 - $173,425	1,481 Added 34.79%	5,738 $645,000
Q2 2023 Aug 09, 2023	BUY	$89.53 - $104.87 $149,067 - $174,608	1,665 Added 64.24%	4,257 $401,000
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $41,502 - $54,251	441 Added 20.5%	2,592 $262,000
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $229,554 - $273,306	2,151 New	2,151 $256,000
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $9,904 - $13,920	-103 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $8,764 - $13,427	103 New	103 $13,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.